Kwarlay.com

Navigating the News Maze with Clarity

Medicine

Sage and Biogen Halt Phase II Study After Novel Drug Shows No Significant Improvement in Treating Essential Tremor

Moving forward, Sage Therapeutics and Biogen intend to cease further clinical development of SAGE-324 for essential tremor.

LEAVE A RESPONSE

Your email address will not be published. Required fields are marked *